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Purpose or Objective: Neoadjuvant chemoradiotherapy 
(CRT) is considered a standard approach for locally invasive 
rectal cancer. Several phase 3 studies have shown an 
improvement in local control with combined radiotherapy 
and capecitabine / 5-fluorouracil. There is good evidence 
that increased dose of radiotherapy is associated with both 
better pathological response and survival in many 
malignancies, although the data in rectal cancer is less 
convincing. In this study we assessed the impact of dose-
escalated radiotherapy on pathological outcome. 
 
Material and Methods: We evaluated all patients who 
received chemo-radiotherapy for rectal cancer and 
subsequently had an anterior resection/ abdominoperineal 
resection with a total mesorectal excision (TME) between 
February 2012 and December 2014. Patients received 50.4Gy 
1.8Gy fractions, and more recently those who have T3/4 
disease with a threatened circumferential margin had a 
simultaneous integrated boost of the primary tumour to a 
total dose of 53.2Gy, with concurrent capecitabine 
chemotherapy (825mg/m2 BD) daily throughout treatment. 
Treatment was initially using 3-D conformal radiotherapy but 
more recently has been using a VMAT technique with cone 
beam CT used during treatment. Surgery was performed 8-12 
weeks after completion of CRT.The primary end point was 
pathological response (Dworak score 0-4) of the operative 
specimen. Scores of 0-2 were considered to be non-
pathological responders and scores of 3-4 were considered to 
be pathological responders. 
 
Results: A total of 73 patients received neoadjuvant 
chemoradiotherapy. 61 patients weretreated with a standard 
radiotherapy fractionation of 50.4Gy in 28 fractions (Group A) 
and 12 patients were treated with a dose escalated 
fractionation to the primary tumour of 53.2Gy in 28 fractions 
(Group B). The rate of pathological response was 39.3% in 
Group A and 86.7% with Group B (t=3.55, p<0.001). 
 
Conclusion: This study demonstrates the beneficial effects of 
dose-escalated radiotherapy and wetherefore recommend 
this regime be considered for inclusion in future phase 2 
studies. 
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Purpose or Objective: Early proctoscopy (1 year) can predict 
late rectal mucosa changes and therefore can be used as 
surrogate end-point for late rectal toxicity. The aim of this 
study was to retrospectively analyze data of patients treated 
at a single institution, consecutively enrolled in different 
prospective clinical trials, trying to determine a correlation 
between treatment parameters and VRS (Vienna Rectoscopy 
Score) recorded at 1-year proctoscopy. 
 
Material and Methods: Patients with prostate 
adenocarcinoma treated with curative or adjuvant RT 
underwent endoscopy one year after RT; 195 patients were 
included in this analysis. Correlations between VRS > 2 and 
several treatment parameters were investigated by 
univariate and multivariate logistic analysis. 
 
Results: Patients treated with an EQD2 dose > 75 Gy, with 
hypofractionatied schedule and radiosurgery boost had a 
higher incidence of VRS > 2 (p= < 0.001). On the contrary, 
previous surgery and 3D-conformal radiotherapy (vs IMRT) 
were associated with a lower incidence of rectal mucosal 
changes (p=< 0.001; p= 0.003, respectively). At multivariate 
analysis radiosurgery boost was associated with the highest 
odd ratios for the risk of developing a VRS > 2 (OR: 4.143; CI: 
1.24-13.81; p=0.001). Even surgery showed a significant 
correlation with VRS > 2 (OR: 0.39; CI: 0.17-9.94; p=0.037, 
Table 1). 
 
 
 
Conclusion: Prolonged patients follow-up is needed to 
“clinically” confirm the increased rectal toxicity produced by 
radiosurgery boost. 
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Purpose or Objective: The objective of the study is to 
determine the correlations among the variables of dose and 
the sphincter function (SF) in patients with locally advanced 
rectal cancer treated with preoperative 
capecitabine/radiotherapy followed by Local Anterior 
Resection(LAR) +TME. 
 
Material and Methods: We have retrospectively reviewed 92 
consecutive patients with LARC treated at our center with 
LAR from 2006 and more than 1 year free from disease. We 
re-contoured the anal sphincters (AS) of patients with the 
help of the radiologist. SF was assessed with the Wexner 
scale (0-20 points, being punctuation inversely proportional 
to SF). All questionnaires were filled out between January 
2010 and December 2012. Dosimetric parameters that have 
been studied include: V20 V30, V40, V50, mean dose 
(Dmean), mínimum dose (Dmin), D90 (dose received by 90% 
of the sphincter) and D98 Statistical analysis: the correlations 
